Predictive Oncology Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raymond F. Vennare
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 2915 Commers Drive Pittsburgh MN United States of America 55121
- IPO Date
- May 3, 2010
- CIK
- 0001446159
- Website
- predictive-oncology.com
- Similar Companies
- Business
- Predictive Oncology Inc. (NASDAQ: POAI), headquartered in Pittsburgh, Pennsylvania and founded in 2002, applies artificial intelligence and machine learning to accelerate oncology drug discovery and development through its proprietary PEDAL platform, which predicts drug responses with high accuracy using data from the world's largest privately held biobank of over 150,000 heterogeneous human tumor samples; 3D organoid models that replicate human tissue microenvironments for clinically relevant drug testing; CLIA-certified laboratory services encompassing biomarker identification, immunohistochemistry, genomics, proteomics, and companion diagnostics validation; and clinical research support including biorepository management. The company serves biopharma partners globally by optimizing drug candidate selection, addressing tumor heterogeneity early in development, and enhancing clinical trial success probabilities via active machine learning validated against wet-lab experiments. In March 2025, Predictive Oncology completed the sale of its Skyline Medical subsidiary's assets—including the FDA-cleared STREAMWAY System for automated medical fluid waste management—to DeRoyal Industries, enabling sharper focus on core AI-driven oncology solutions ahead of its pending merger with Renovaro Biosciences; in September 2025, it announced a strategic collaboration with Every Cure to pursue drug repurposing opportunities leveraging its AI platform and biobank; and later that month, it secured private placement funding expected to close in early October 2025 to support business expansion including a digital asset treasury strategy with partner Aethir. Previously known as Precision Therapeutics Inc., the company renamed to Predictive Oncology in June 2019 and operates primarily from facilities in Pittsburgh with historic segments in Eagan, Minnesota, and Birmingham, targeting pharmaceutical manufacturers, academic researchers, and oncology therapeutics developers worldwide.
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
Predictive Oncology Q4 Earnings Call Highlights
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI)
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
Predictive Oncology Announces 1-for-15 Reverse Stock Split
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Court Denies Renovaro Motion for an Expedited Trial in July
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology